Twitter : @EFPIA
Website : www.efpia.eu
Overview
Mentions in press and media 13
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 16, 2025 | The Glyphosate Gamble: Georgia's New Law and the Future of Agriculture | In a bold move, Georgia has become the second state in the U.S. to shield Bayer, the maker of Roundup, from certain cancer claims. This law, set to take effect on January 1, 2026, is a double-edged sword. It aims to protect farmers and the ... |
| May 15, 2025 | Denmark’s economy boomed on drug exports — Trump’s tariffs threat won’t be what slows it down | Denmark’s economic growth, which was driven by what economists described as an “exceptional surge” in pharmaceutical exports, is expected to weaken this year. The looming threat of U.S. tariffs on the pharma industry won’t be much of a fact... |
| Apr 9, 2025 | European stocks close 3.5% lower as Trump tariffs take effect, China and EU retaliate | This was CNBC’s live blog covering European markets. European stocks closed sharply lower on Wednesday, with Tuesday’s market rebound proving short-lived as the U.S.′ country-specific tariffs started taking effect. The pan-European Stoxx 60... |
| Apr 3, 2025 | 23andMe's Rocky Road: A Genetic Gamble in Bankruptcy | The story of 23andMe is a tale of ambition, innovation, and now, a desperate scramble for survival. Once a beacon of hope in the consumer genetics landscape, the company has hit a wall. It filed for Chapter 11 bankruptcy protection, a move ... |
| Apr 2, 2025 | 2025 ISPE Europe Annual Conference Debuts New Workshops and Announces Keynote Speakers | The 2025 ISPE Europe Annual Conference plans to have strong regulatory participation from European health authorities. The 2025 ISPE Europe Annual Conference will take place 12 – 14 May in London, United Kingdom (UK), and virtually. NORTH B... |
| Jan 15, 2025 | Increasing Participation in Muscular Dystrophy Clinical Trials | Michel van Harten M.D., CEO of myTomorrows Muscular Dystrophy (MD) refers to a group of rare genetic conditions that cause progressive muscle weakness and degeneration in patients. Some forms of MD, such as Duchenne Muscular Dystrophy (DMD)... |
| Oct 20, 2023 | How to make the EU’s new Joint Clinical Assessment process work for industry — and for patients | Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contri... |
| Sep 30, 2022 | European pharma group wants to create PRV-like system to spur antibiotics R&D | New research funded by a European pharma industry group is looking to reinvigorate antimicrobial R&D with a system that’s similar to the priority review voucher systems in the US, which spurs new research in rare... |
| Jun 10, 2022 | Waiving intellectual property rights is a flawed solution to achieving Covid-19 vaccine equity | When the history of the Covid-19 pandemic is written, readers will be as stunned by the flagrant collective flaw in not getting vaccines to all those who needed them as they will by the remarkable successes in vaccine and drug development. ... |
Reviews 0
FAQ about EFPIA
When was EFPIA founded?
EFPIA was founded in 1978.
What has the press written about EFPIA?
Parsers VC has collected 13 articles mentioning EFPIA, among them “The Glyphosate Gamble: Georgia's New Law and the Future of Agriculture” (May 16, 2025) and “Denmark’s economy boomed on drug exports — Trump’s tariffs threat won’t be what slows it down” (May 15, 2025).
Is EFPIA still active?
Yes, EFPIA is active; its latest activity on Parsers VC dates from Oct 10, 2025.